Last reviewed · How we verify
NCT02964689
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
Phase 1 trial testing Binimetinib in Advanced Non-small Cell Lung Cancer in 18 participants. Completed in 2 July 2021.
2 July 2021
Quick facts
| Lead sponsor | Swiss Cancer Institute |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 12 April 2017 |
| Primary completion | 2 July 2021 |
| Estimated completion | 2 July 2021 |
| Sites | 4 locations across Switzerland |
Drugs / interventions tested
- Binimetinib (binimetinib) — full drug profile →
- Pemetrexed — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
Conditions studied
- Advanced Non-small Cell Lung Cancer — all drugs for Advanced Non-small Cell Lung Cancer →
- KRAS Gene Mutation — all drugs for KRAS Gene Mutation →
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Swiss Cancer Institute
Who can join
Adults 18 to 75, any sex, with Advanced Non-small Cell Lung Cancer or KRAS Gene Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim is to determine the recommended phase 2 dose (RP2D) of binimetinib in combination with pemetrexed and cisplatin, and to demonstrate that the combination is feasible and has preliminary activity in previously untreated patients with advanced NSCLC and documented KRAS mutations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02964689
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Binimetinib
Trials testing the same drug.
- NCT05554354 — Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastat · Phase 2 · terminated
- NCT05564403 — Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH T · Phase 2 · active not recruiting
- NCT04870034 — Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic C · EARLY_PHASE1 · withdrawn
- NCT05554367 — Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial · Phase 2 · active not recruiting
- NCT05304546 — Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma · Phase 2 · completed
Other recruiting trials for Advanced Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06868732 — Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC · Phase 1 · recruiting
- NCT06452277 — A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip · Phase 3 · recruiting
- NCT06269133 — Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non- · active not recruiting
- NCT06043973 — Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance · Phase 3 · recruiting
- NCT05416775 — Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
Other Swiss Cancer Institute trials
Trials by the same sponsor.
- NCT07158489 — Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC · Phase 2 · not yet recruiting
- NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
- NCT06452394 — NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline · Phase 2 · recruiting
- NCT06114108 — Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients · NA · recruiting
- NCT04629781 — Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02964689 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Swiss Cancer Institute
- Last refreshed: 14 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02964689.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing